Karyopharm Therapeutics (NasdaqGS:KPTI) Q3 2025 Earnings Call November 03, 2025 08:00 AM ET Speaker3Morning. My name is Ludi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics third quarter 2025 financial results conference call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Brendan Strong, Senior Vice Presid ...

Richard Paulson, President and Chief Executive Officer • Phase 3 SENTRY Trial and Myelofibrosis Review Third Quarter 2025 Financial Results & Business Update November 3, 2025 On Today's Call • Welcome Brendan Strong, SVP, Investor Relations and Corporate Communications • Overview Dr. Reshma Rangwala, Chief Medical Officer and Head of Research • Commercial Highlights and Myelofibrosis Commercial Opportunity Sohanya Cheng, Chief Commercial Officer and Head of Business Development • Financial Results and Guida ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR (State or other jurisdiction of incorporation or organization) 85 Wells Avenue, 2nd Floor Newton, MA 02459 (Address of principal executive offices) (Zip Code) Delaware 26-3931704 (I.R.S. Employer Identification Number) (617) 658-0600 ☐ TRANSITION REPORT PURS ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Accessibility StatementSkip Navigation Endometrial Cancer – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – –Â Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – – Â Conference Call Scheduled for Today at 8:00 ...

根据提供的文档内容，该文档不包含任何与公司或行业相关的实质性信息 无法提取投资相关的核心观点或关键要点

技术分析 - 公司50日简单移动平均线上穿200日简单移动平均线 形成黄金交叉 这是一个关键的技术图表形态 可能预示着看涨突破 [1] - 黄金交叉的形成包含三个阶段 股价下跌趋势见底 短期移动平均线上穿长期移动平均线引发趋势反转 股价持续上涨动能 [2] - 在过去四周内 公司股价上涨5.2% [3] 市场预期与评级 - 公司目前Zacks评级为第3级（持有） 表明股票可能即将突破 [3] - 当前季度的盈利预期在过去60天内获得2次上调 无下调 Zacks共识预期也已上调 [3] - 鉴于重要的技术指标和盈利预期的积极变动 投资者应考虑将公司纳入观察名单 [5]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying PANW stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

Several biotech stocks posted notable after-hours gains on Thursday, October 9, driven by fresh data, strategic updates, and corporate developments. Here's a quick look at the key movers and catalysts.Shares of Palisade Bio Inc. (PALI) traded at $2.26 in the after-hours session as of 9:16 PM EDT on October 9, reflecting a 7.62% gain from the prior close. The stock had ended Thursday's regular session at $2.10, up 5% on the day. Over the past 52 weeks, PALI has ranged between $0.53 and $4.32.The after-hours ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with  $100 million of financial flexibility and additional capital, extending the cash runway into the second quarter of 2026.KPTI is among today’s weakest performers. See what is happening here.Karyopharm said it continues exploring potential financing and strategic alternatives to enhance liquidity and maximize value. Centerview Partners is the financ ...